Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against bluebird bio, Inc.

NEW YORK, February 17, 2021 / PRNewswire / – Bernstein Liebhard, a nationally recognized investor rights law firm, has announced that a class action lawsuit has been filed on behalf of investors who have purchased or acquired the securities of bluebird bio, Inc. (“bluebird” or the “Company”) “) (NASDAQ: BLUE) by May 11, 2020 by 4th November 2020(the “Class Period”). The lawsuit has been filed The United States District Court for the Eastern District of new York alleges violations of the Securities Exchange Act of 1934.

If you have purchased Bluebird securities and / or would like to discuss your legal rights and options, please visit or contact BLUE Shareholder’s class action lawsuit Matthew E. Guarnero toll free at (877) 779-1414 or [email protected]

The complaint alleges that throughout the class period, Defendants made materially false and / or misleading statements and did not provide investors with any information: (i) Data to support Bluebird’s BLA filing for LentiGlobin for SCD was insufficient, to prove the comparability of drugs; (ii) Defendants have downplayed the foreseeable impact of disruptions related to the COVID-19 pandemic on the Company’s BLA filing schedule for LentiGlobin for SCD, particularly with respect to manufacturing. (iii) As a result of all of this, it was foreseeable that the company would not file the BLA for LentiGlobin for SCD in the second half of 2021. and (iv) as a result, the Company’s public statements at all relevant times have been materially false and misleading.

On 4th November 2020Bluebird announced after it was launched that it was not expected to apply for FDA approval for its LentiGlobin product for the treatment of SCD in the second half of 2021. Citing “feedback” from the FDA that the company is required to provide additional data “to demonstrate drug comparability” for LentiGlobin for SCD “in addition to COVID-19 related shifts and COVID-19 impact on contract manufacturing”, Bluebird passed the submission date until the end of 2022.

In the news, Bluebird’s share price fell $ 9.72 per share or 16.6% to close at $ 48.83 per share on 5th November 2020.

If you want to appear as the lead plaintiff, you have to move the court at the latest April 13, 2021. A lead plaintiff is a representative party who acts on behalf of other class members in directing the dispute. Your ability to partake in a recovery does not require you to be the lead plaintiff. If you don’t take action, you may remain an absent class member.

If you have purchased Bluebird securities and / or would like to discuss your legal rights and options, please visit https://www.bernlieb.com/cases/bluebirdbioinc-blue-shareholder-class-action-lawsuit-stock-fraud-361 / apply / or contact Matthew E. Guarnero toll free at (877) 779-1414 or [email protected]

Bernstein Liebhard LLP has recovered since 1993 $ 3.5 billion for its customers. In addition to representing individual investors, the firm has been hired by some of the largest public and private pension funds in the country to monitor their assets and litigate on their behalf. Based on the success of hundreds of lawsuits and class actions, the firm has been featured on the National Law Journal’s “Hot List” thirteen times and on The Legal 500 for ten consecutive years.

LAWYER. © 2021 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779- 1414. The lawyer responsible for this complaint in the State of Connecticut is Michael S. Bigin. Past results do not guarantee or forecast a similar result with respect to future matters.

Contact information

Matthew E. Guarnero
Bernstein Liebhard LLP
https://www.bernlieb.com
(877) 779-1414
[email protected]

SOURCE Bernstein Liebhard LLP

similar links

http://www.bernlieb.com

Comments are closed.